NASDAQ$PODD

Insulet Corp. · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Reported an 18% year-over-year increase in revenue.

Insulet Corporation reported a strong third quarter with revenue reaching $275.6 million, an increase of 17.8% compared to the prior year. The company saw growth across its Omnipod product line, particularly in the U.S., and achieved record new customer starts. Insulet is on track for Omnipod 5 clearance later this year.

  • Third quarter revenue reached $275.6 million, up 17.8% year-over-year.
  • Total Omnipod revenue increased by 22.7% to $260.3 million.
  • U.S. Omnipod revenue grew by 26.4% to $167.2 million.
  • Operating income was $33.7 million, representing 12.2% of revenue.

Headline financials

Total Revenue

$276M

Previous: $234M+17.8%
EPS (adj)

$0.18

Previous: $0.17+5.9%
Gross Margin

68.5%

Previous: 64.9%+5.5%
Adjusted EBITDA

$55.7M

Previous: $42.3M+31.7%
Capital Expenditures

-$80.1M

Previous: -$88.5M+9.5%
Free Cash Flow

-$67.5M

Previous: -$76.9M+12.2%
Net Income

$12.6M

Previous: $11.6M+8.6%
Operating Income

$33.7M

Previous: $23.8M+41.6%
Gross Profit

$189M

Previous: $152M+24.3%
Cash & Equivalents

$857M

Previous: $838M+2.2%
Total Assets

$2B

Previous: $1.71B+16.9%
Stock-Based Comp

$8.2M

Previous: $6.6M+24.2%

Revenue & EPS history

Insulet · Revenue · Quarterly

$276M

Q3 2021+17.8%vs Q3 2020
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Insulet · $276M total across 3 segments · Q3 2021

  • U.S. Omnipod
    $167M+26.4%
  • International Omnipod
    $93.1M+16.7%
  • Drug Delivery
    $15.3M-30.1%

Forward guidance

The Company expects revenue growth of 19% to 25% for the quarter ending December 31, 2021. Revenue growth ranges by product line are: Total Omnipod of 17% to 22%, U.S. Omnipod of 22% to 27%, International Omnipod of 7% to 13%, and Drug Delivery of 45% to 65%.

Tailwinds

  • Total Omnipod revenue growth of 17% to 22%
  • U.S. Omnipod revenue growth of 22% to 27%
  • International Omnipod revenue growth of 7% to 13%
  • Drug Delivery revenue growth of 45% to 65%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.2%

Avg return

30 days after

65%

41 / 63 earnings

Positive

+20.7%

Q1 2025

Best reaction

-16.8%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+3.8%+1.4%
Q4 2025+3.5%+1.2%-7.8%
Q3 2025+2.8%+3.8%-3.2%
Q1 2025+20.7%+25.1%+21.3%
Q4 2024-1.9%-6.1%-6.9%
Q3 2024+12.0%+15.0%+10.9%
Q2 2024-4.3%+2.2%+12.8%
Q1 2024-5.5%-1.9%+9.0%
Q4 2023-4.3%-13.4%-14.6%
Q3 2023+18.1%+17.5%+39.6%
Q2 2023-11.9%-13.6%-31.6%
Q1 2023+2.4%-0.4%-12.4%
Q4 2022+2.3%-4.0%+7.8%
Q3 2022+19.6%+16.3%+17.7%
Q2 2022+2.4%-0.8%-2.5%
Q1 2022-16.8%-23.0%-13.9%
Q4 2021+8.9%+12.9%+7.4%
Q3 2021-1.3%+2.0%-15.6%
Q2 2021-1.3%+0.1%+8.4%
Q1 2021-11.4%-13.0%+2.8%
Q4 2020+2.3%+1.0%+1.0%
Q3 2020+14.6%+14.4%+16.0%
Q2 2020+1.1%-7.7%-4.9%
Q1 2020+5.4%+6.8%-13.3%
Q4 2019-13.2%-8.4%-14.2%
Q3 2019+9.9%+16.4%+26.5%
Q2 2019+18.4%+26.0%+30.0%
Q1 2019+14.0%+20.9%+29.4%
Q4 2018+5.1%+7.7%+6.6%
Q3 2018+0.4%-2.4%-4.9%
Q2 2018+2.4%+2.6%+24.3%
Q1 2018-3.6%-4.3%+9.0%
Q4 2017+3.6%-1.1%+8.6%
Q3 2017+18.9%+22.7%+21.0%
Q2 2017+6.5%+8.6%+15.5%
Q1 2017-5.8%-4.6%+0.9%
Q4 2016-5.2%+0.7%-7.2%
Q3 2016+9.9%+10.3%+3.9%
Q2 2016+18.5%+23.3%+22.2%
Q1 2016-4.0%
Q4 2015+9.0%
Q3 2015+13.2%
Q2 2015+10.0%
Q1 2015-11.0%
Q4 2014-4.5%
Q3 2014+5.1%
Q2 2014-2.2%
Q1 2014-14.0%
Q3 2013-3.4%
Q2 2013+10.2%
Q1 2013+12.0%
Q4 2012+9.3%
Q3 2012+4.2%
Q2 2012+4.8%
Q1 2012+2.1%
Q4 2011-3.5%
Q3 2011+0.5%
Q2 2011+2.9%
Q1 2011+0.6%
Q4 2010-2.0%
Q3 2010+2.5%
Q2 2010+0.3%
Q1 2010+11.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro